Amgen acquires BioVex Group

Amgen acquires BioVex Group

News and Articles
Mar 4 2011

Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc. The transaction provides Amgen with BioVex’s lead product candidate, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on January 24, 2011. 

Harris & Harris Group was an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.

Source:

Harris & Harris Group

Source: www.news-medical.net

Rate article
Add a comment